Human milk in the modern world

Sir,

In her recent review of our book Mavis Gunther (whose work we have admired greatly) seems to have cast us as a blend of brainless (if amiable) zealots, fundamental evangelists, and self-deluded visionaries.

Perhaps our strong secular advocacy is because our perspectives are very different from hers. Our main concerns are with disadvantaged communities (mainly in the third world), where breast feeding is vital for survival in early childhood, rather than ideal as in industrialised parts of the world.

Dr Gunther has misconstrued several concerns expressed by us. For example, the phrase 'statutory legislation for breast feeding' used in her review suggests forced breast feeding camps. In fact, in our book we discuss the legislation that is needed to make it easier for working women to breast feed should they wish to do so—scarcely wild-eyed evangelism, as this is already the practice in some parts of the world.

In essence, what may be called a Calcutta-eye view of infant feeding is very different from a London-eye view. In the third world breast feeding is one of the main components of primary health care in relation to nutrition, water supply, infection, economics, self sufficiency in food production, and child spacing^ and as such it deserves activist advocacy.

Reference


Dr Gunther comments:
I hope that the Jelliffes can bring themselves to read my review again. My words were 'statutory powers to enable working mothers to feed their babies' which to me mean that the choice remains with the mother. Surely we are saying the same thing?

Mavis Gunther
77 Ember Lane,
Esher, Surrey KT10 8EG

Treatment of hypophosphataemic vitamin D-resistant rickets

Sir,

We read with interest the paper by Seino et al. Our experience with 1-α-hydroxy-vitamin D₃ (1αOHD₃) in the treatment of this disease is limited to one patient—a 2-year-old girl. The diagnosis was based on rickets, hypophosphataemia, raised alkaline phosphatase, normal serum calcium, and normal serum parathyroid hormone. She has been treated for 2 months with daily administration of 0.5 μg 1αOHD₃ and about 2 g phosphate. Radiological examination already shows partial healing of bone (Figure, a and b).

Contrary to Seino et al. we have only used small doses of 1αOHD₃ and we are astonished that the high doses used by them should be necessary, particularly as the risk of side effects and the cost of the treatment are increased.

Jan H Kristiansen and Vibeke Faurholt Pedersen
Department of Paediatrics,
Odense University Hospital,
5000 Odense, Denmark

Reference


Figure Roentgenograms of right knee, showing the changes in bone structure. (a) Before treatment, and (b) after 2 months' treatment.